Clinicopathological features and the impact of the new TNM classification of malignant tumors in patients with pulmonary large cell neuroendocrine carcinoma

Iyoda,Akira; Jiang,Shi‑Xu; Travis,William  D.; Kurouzu,Naomi; Ogawa,Fumihiro; Amano,Hideki; Sato,Yuichi; Rusch,Valerie  W.; Saegusa,Makoto; Satoh,Yukitoshi

doi:10.3892/mco.2013.80

Clinicopathological features and the impact of the new TNM classification of malignant tumors in patients with pulmonary large cell neuroendocrine carcinoma

Authors:
- Akira Iyoda
- Shi‑Xu Jiang
- William D. Travis
- Naomi Kurouzu
- Fumihiro Ogawa
- Hideki Amano
- Yuichi Sato
- Valerie W. Rusch
- Makoto Saegusa
- Yukitoshi Satoh
View Affiliations

Affiliations: Department of Thoracic Surgery, Kitasato University, School of Medicine, Kanagawa 252-0374, Japan, Department of Pathology, Kitasato University, School of Medicine, Kanagawa 252-0374, Japan, Department of Pathology, Thoracic Service, Memorial Sloan‑Kettering Cancer Center, New York 10065, USA, Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Kanagawa 252-0374, Japan, Department of Surgery, Thoracic Service, Memorial Sloan‑Kettering Cancer Center, New York 10065, USA
Published online on: February 28, 2013 https://doi.org/10.3892/mco.2013.80
Pages: 437-443

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The prognosis of patients with large‑cell neuroendocrine carcinoma (LCNEC) of the lung is extremely poor and the optimal treatment for these patients has yet to be determined. In this study, we described the clinicopathological characteristics of LCNECs and compared the prognoses of corresponding stages determined by the guidelines of the 6th and 7th editions of the TNM classification of malignant tumors. Clinical data from 42 patients diagnosed with primary LCNEC who underwent treatment at Kitasato University Hospital between 1991 and 2009 were retrospectively analyzed. On follow‑up of 42 patients, 22 (52.4%) had confirmed recurrent tumors, including 8 patients with mediastinal lymph node recurrences and 19 with distant metastases. The sites of distant metastases included the brain in 8, bone in 8, liver in 7, lungs in 5 and adrenal glands in 4 patients. For all the patients, the 5‑year overall survival rate was 34.7% and the 5‑year disease‑free survival rate was 32.9%. The 5‑year overall survival rates of patients with stage I cancers according to the 6th and 7th staging editions was 51.3% (6th n=18, 7th n=16). Thirteen of 42 patients (31.0%) also had metachronous or synchronous primary cancers. Patients with LCNEC had poor outcomes, even those with stage I tumors classified according to the 7th edition of the TNM classification. Therefore, frequent recurrences in addition to metachronous or synchronous primary cancers in patients with LCNEC should be treated.

View Figures

View References

1.	Travis WD, Colby TV, Corrin B, Shimosato Y and Brambilla E: Histological Typing of Lung and Pleural Tumours. World Health Organization International Histological Classification of Tumors, XIII. 3rd edition. Springer-Verlag; Berlin/Heidelberg: 1999
2.	Iyoda A, Hiroshima K, Nakatani Y and Fujisawa T: Pulmonary large cell neuroendocrine carcinoma: its place in the spectrum of pulmonary carcinoma. Ann Thorac Surg. 84:702–707. 2007.PubMed/NCBI
3.	Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Fujisawa T and Ohwada H: Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer. 91:1992–2000. 2001. View Article : Google Scholar : PubMed/NCBI
4.	Asamura H, Kameya T, Matsuno Y, et al: Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 24:70–76. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Iyoda A, Hiroshima K, Moriya Y, et al: Pulmonary large cell neuroendocrine carcinoma demonstrates high proliferative activity. Ann Thorac Surg. 77:1891–1895. 2004. View Article : Google Scholar : PubMed/NCBI
6.	Iyoda A, Hiroshima K, Baba M, Saitoh Y, Ohwada H and Fujisawa T: Pulmonary large cell carcinomas with neuroendocrine features are high-grade neuroendocrine tumors. Ann Thorac Surg. 73:1049–1054. 2002. View Article : Google Scholar : PubMed/NCBI
7.	Onuki N, Wistuba II, Travis WD, et al: Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer. 85:600–607. 1999. View Article : Google Scholar : PubMed/NCBI
8.	Jones MH, Virtanen C, Honjoh D, et al: Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet. 363:775–781. 2004. View Article : Google Scholar
9.	Hiroshima K, Iyoda A, Shibuya K, et al: Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma. Cancer. 100:1190–1198. 2004. View Article : Google Scholar : PubMed/NCBI
10.	Goldstraw P, Crowley J, Chansky K, et al: International Association for the Study of Lung Cancer International Staging Committee. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007.
11.	Jiang SX, Kameya T, Shoji M, Dobashi Y, Shinada J and Yoshimura H: Large cell neuroendocrine carcinoma of the lung. A histologic and immunohistochemical study of 22 cases. Am J Surg Pathol. 22:526–537. 1998. View Article : Google Scholar : PubMed/NCBI
12.	Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar
13.	Veronesi G, Morandi U, Alloisio M, et al: Large cell neuroendocrine carcinoma of the lung: A retrospective analysis of 144 surgical cases. Lung Cancer. 53:111–115. 2006. View Article : Google Scholar : PubMed/NCBI
14.	Takei H, Asamura H, Maeshima A, et al: Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg. 124:285–292. 2002. View Article : Google Scholar : PubMed/NCBI
15.	Rossi G, Cavazza A, Marchioni A, et al: Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol. 23:8774–8785. 2005. View Article : Google Scholar : PubMed/NCBI
16.	Travis WD, Rush W, Flieder DB, et al: Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 22:934–944. 1998. View Article : Google Scholar : PubMed/NCBI
17.	Paci M, Cavazza A, Annessi V, et al: Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study. Ann Thorac Surg. 77:1163–1167. 2004.PubMed/NCBI
18.	Battafarano RJ, Fernandez FG, Ritter J, et al: Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg. 130:166–172. 2005. View Article : Google Scholar : PubMed/NCBI
19.	Skuladottir H, Hirsch FR, Hansen HH and Olsen JH: Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer. 37:127–135. 2002. View Article : Google Scholar : PubMed/NCBI
20.	Iyoda A, Hiroshima K, Moriya Y, et al: Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. J Thorac Cardiovasc Surg. 138:446–453. 2009. View Article : Google Scholar : PubMed/NCBI
21.	Yamazaki S, Sekine I, Matsuno Y, et al: Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer. 49:217–223. 2005. View Article : Google Scholar : PubMed/NCBI
22.	Iyoda A, Hiroshima K, Toyozaki T, et al: Adjuvant chemotherapy for large cell carcinoma with neuroendocrine features. Cancer. 92:1108–1112. 2001. View Article : Google Scholar : PubMed/NCBI
23.	Iyoda A, Hiroshima K, Moriya Y, et al: Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg. 82:1802–1807. 2006. View Article : Google Scholar : PubMed/NCBI
24.	Kamiyama H, Ikeya T, Suda K, Murai K, Aoyama K and Hoshi E: Second primary digestive cancer after resection of lung cancer. Surg Today. 34:577–580. 2004. View Article : Google Scholar : PubMed/NCBI
25.	Battafarano RJ, Force SD, Meyers BF, et al: Benefits of resection for metachronous lung cancer. J Thorac Cardiovasc Surg. 127:836–842. 2004. View Article : Google Scholar : PubMed/NCBI
26.	Johnson BE: Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst. 90:1335–1345. 1998. View Article : Google Scholar : PubMed/NCBI